MediLink reported Phase 3 results for a Roche-partnered antibody-drug conjugate in small-cell lung cancer, saying the trial met its primary endpoint. However, the company said median overall survival fell short of the benchmark set by GSK’s rival asset in cross-trial comparisons. The outcome illustrates the difficulty of translating “endpoint wins” into competitive positioning when survival—often the decisive differentiator—lands below market expectations. For B7-H3-directed ADCs, the next phase of scrutiny will likely focus on how to interpret OS against rival datasets and whether follow-on analyses support differentiated value in subgroups.